GI
DMAC icon

GAMMA Investing’s DiaMedica Therapeutics DMAC Stock Holding History

GAMMA Investing’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43K Sell
203
-164
-45% -$1.01K ﹤0.01% 3794
2026
Q1 		$2.48K Buy
367
+265
+260% +$2.1K ﹤0.01% 3593
2025
Q4 		$812 Hold
102
– – ﹤0.01% 3842
2025
Q3 		$701 Buy
+102
New +$553 ﹤0.01% 3667

Other funds holding DMAC

MW
Members Wealth Media, Pennsylvania $182M AUM 15.09% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing's DMAC Position: Q2 2026 in Review

GAMMA Investing reduced its DiaMedica Therapeutics (DMAC) stake by 45% in Q2 2026, selling an estimated $1.01K and leaving 203 shares worth $1.43K. The position accounts for ﹤0.01% of the portfolio, ranked #3794.

GAMMA Investing first reported a position in DMAC in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.48K in Q1 2026. 6 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • GAMMA Investing held 203 shares of DiaMedica Therapeutics worth $1.43K as of Q2 2026.
  • GAMMA Investing sold 164 DiaMedica Therapeutics shares in Q2 2026, an estimated $1.01K.
  • DiaMedica Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3794 holding.
  • GAMMA Investing first reported a position in DiaMedica Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • GAMMA Investing's DiaMedica Therapeutics position peaked at $2.48K in Q1 2026.
  • 6 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.